Apathy in Late-Life Depression: Common, Persistent, and Disabling

Abstract

Objectives The aims of this study were to examine: (1) the relationship between apathy and disability in late-life depression, and (2) the functional significance of improvement in apathy following escitalopram treatment in terms of its relationship to disability. Methods Subjects were 71 non-demented elderly with non-psychotic major depression. After a 2-week single-blind placebo period, subjects who had Hamilton Depression Rating Scale (HDRS) ≥ 18 received escitalopram 10mg daily for 12 weeks. Apathy and disability were assessed with the Apathy Evaluation Scale (AES) and the World Health Organization Disability Assessment Scale II (WHODAS) respectively. These measures and the HDRS were administered at baseline and again following 12 weeks of treatment. Results At baseline, 38% of depressed subjects had significant apathy (AES ≥ 36.5). Severity of apathy at baseline significantly correlated with severity of disability. In a multivariate regression model, baseline severity of apathy, but not the overall depressive syndrome (HDRS), significantly correlated with baseline disability. Following escitalopram treatment, improvement in apathy significantly correlated with improvement in disability measures, while change in the rest of the depressive syndrome did not. The overall change in apathy and disability in response to escitalopram treatment was significant but small. Conclusions Apathy is common in late-life depression and is associated with disability above and beyond the influence of other depressive symptoms. Given the strong relationship between apathy and disability, understanding the neurobiology of apathy and developing treatments for apathy may improve the functional outcomes of late-life depression.

Apathy in Older Patients with Type 2 Diabetes

“…The symptoms of apathy frequently overlap with depression but apathy is a syndrome distinct from clinical depression (6). The adverse consequences of apathy that have been documented include decreased recovery following stroke (7), increased stress in dementia caregivers and greater disability in depressed individuals (2,8). In Alzheimer's disease, apathy is a significant predictor of cognitive and functional decline, depression and parkinsonism (4).…”

“…Baseline PHQ-9 scores were also significantly different among the four conditions (Kruskall-Wallis H test, chi-square 8.29, df 3, P=0.04 ) with lower median depression scores at baseline (that approached statistical significance) in recovered compared with persistent apathy (2[2][3][4] vs 13[7][8][9][10][11][12][13][14][15][16], P=0.053). There were no differences in MMSE scores (Kruskall-Wallis H test, chi-square 6.63, df 3, P=0.09).…”

A survey on the prevalence of apathy in elderly people referred to specialized memory centers

“…2 Apathy is very common in elderly people with neurocognitive and psychiatric disorders. 5 It is also found among important proportions of individuals following stroke and traumatic brain injury 6 and in psychiatric conditions such as major depressive disorders 7 and schizophrenia. 5 It is also found among important proportions of individuals following stroke and traumatic brain injury 6 and in psychiatric conditions such as major depressive disorders 7 and schizophrenia.…”

Assessing bipolar disorder in the older adult: the GERI‐BD toolbox

“…We assessed behavioral functioning with the 12‐item World Health Organization Disability Assessment Schedule II (WHODAS II; Epping‐Jordan and Ustun, ). It is used across all diseases and ages (Banerjee et al ., ; Yuen et al ., ), is cross‐culturally applicable, and assesses disability level and overall functioning. The WHODAS II addresses functioning in six domains: (1) understanding and communicating; (2) getting around; (3) self‐care; (4) getting along with others; (5) household and work activities; and (6) participation in society.…”